Arg9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Di-methylation Site Page: > Arg9  -  PSF (human)

Site Information
SRDRFrsrGGGGGGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 476747

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 )
Disease tissue studied:
cervical cancer ( 10 ) , cervical adenocarcinoma ( 10 ) , colorectal cancer ( 7 , 8 , 9 ) , colorectal carcinoma ( 7 , 8 , 9 )
Relevant cell line - cell type - tissue:
HCT116 (intestinal) ( 2 , 5 , 6 , 7 , 8 , 9 ) , HeLa S3 (cervical) ( 3 , 10 ) , Jurkat (T lymphocyte) ( 1 , 4 ) , T lymphocyte ( 1 )

References 

1

Geoghegan V, et al. (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling. Nat Commun 6, 6758
25849564   Curated Info

2

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

3

Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837   Curated Info

4

Uhlmann T, et al. (2012) A method for large-scale identification of protein arginine methylation. Mol Cell Proteomics 11, 1489-99
22865923   Curated Info

5

Mulhern D (2012) CST Curation Set: 13536; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

6

Mulhern D (2012) CST Curation Set: 13537; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

7

Possemato A (2010) CST Curation Set: 8849; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

8

Possemato A (2010) CST Curation Set: 8847; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

9

Possemato A (2010) CST Curation Set: 8844; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: mR
Curated Info

10

Ong SE, Mittler G, Mann M (2004) Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 1, 119-26
15782174   Curated Info